Skeletal effects of oral oestrogen compared with subcutaneous oestrogen and testosterone in postmenopausal women.
- 30 July 1988
- Vol. 297 (6644), 331-333
- https://doi.org/10.1136/bmj.297.6644.331
Abstract
STUDY OBJECTIVE--To compare oral and implanted oestrogens for their effects in preventing postmenopausal osteoporosis. DESIGN--Non-randomised cohort study of postmenopausal women treated with oral or depot oestrogens and postmenopausal controls. SETTING--Gynaecological endocrine clinic in tertiary referral centre. PATIENTS--Oral treatment group of 37 postmenopausal women (mean age 57.5 years, median 8.75 years from last menstrual period), compared with 41 women given oestrogen implants (mean age 56.2 years, median 9.5 years from last menstrual period) and 36 controls (mean age 51.8 years, median 2.0 years from last menstrual period). Weight was not significantly different among the groups. INTERVENTIONS--Oral treatment group was given continuous treatment with cyclic oestrogen and progesterone preparations (Prempak C or Cycloprogynova) for a median of 8.0 years. Implant group was given subcutaneous implants of oestradiol 50 mg combined with testosterone 100 mg, on average six monthly for a median of 8.5 years. Controls were not treated. END POINT--Significant increase in bone density. MEASUREMENTS AND MAIN RESULTS--Bone density measured by dual beam photon absorptiometry was 1.02 (SD 0.13) g hydroxyapatite/cm2 in implant group versus 0.89 (0.11) in oral group (p less than 0.01) and 0.87 (0.14) in controls (p less than 0.01). Serum oestradiol concentration in implant group was (median) 725 pmol/l versus 170 pmol/l in oral group (p less than 0.01) and 99 pmol/l in controls (p less than 0.01). Serum follicular stimulating hormone was median 1 IU/l (range 1-11) in implant group (equivalent to premenopausal values) versus 43 (4-94) IU/l in oral group (p less than 0.01) and 72 (28-99) IU/l in controls (p less than 0.01). CONCLUSIONS--Subcutaneous oestrogen is more effective than oral oestrogen in preventing osteoporosis, probably owing to the more physiological (premenopausal) serum oestradiol concentrations achieved. It also avoids problems of compliance that occur with oral treatment.This publication has 20 references indexed in Scilit:
- Hip Fracture and the Use of Estrogens in Postmenopausal WomenNew England Journal of Medicine, 1987
- Compliance with hormone therapyAmerican Journal of Obstetrics and Gynecology, 1987
- Biologic Effects of Transdermal EstradiolNew England Journal of Medicine, 1986
- Pharmacokinetics and pharmacodynamics of transdermal dosage forms of 17β-estradiol: Comparison with conventional oral estrogens used for hormone replacementAmerican Journal of Obstetrics and Gynecology, 1985
- Long‐term effects of the menopause and sex hormones on skin thicknessBJOG: An International Journal of Obstetrics and Gynaecology, 1985
- The use of hormone implants for climacteric symptomsAmerican Journal of Obstetrics and Gynecology, 1984
- HORMONAL PROFILES IN POSTMENOPAUSAL WOMEN AFTER THERAPY WITH SUBCUTANEOUS IMPLANTSBJOG: An International Journal of Obstetrics and Gynaecology, 1981
- BONE MASS IN POSTMENOPAUSAL WOMEN AFTER WITHDRAWAL OF OESTROGEN/GESTAGEN REPLACEMENT THERAPYThe Lancet, 1981
- Procedures in practice. Hormone implantation.BMJ, 1980
- LONG-TERM PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS BY ŒSTROGENThe Lancet, 1976